1.Sales and profit
See section β- Maze Therapeutics, Inc. lost $131M in fiscal 2025.
Maze Therapeutics, Inc.
MAZE Nasdaq Biological Products, (No Diagnostic Substances) Financials FY2024βFY2025
Last close Β· Oct 23, 2026
$31.01
2.9%KIRAβs summary AI analyst
Hi! I read Maze Therapeutics, Inc.βs latest annual report (fiscal 2025). Here is what stands out:
2 to watch
2.Cash and shareholders
See section β- Free cash flow was β$113M in fiscal 2025, β of revenue.
- In the last 12 months, insiders sold $23.7M of shares on the open market and bought none.
Maze Therapeutics, Inc. in 30 seconds
Good So-so Weak
Weak
Does it make a profit?
β$131M
No. It lost money last year.
For information
How is the share priced?
β
No P/E: it made no profit over the last four quarters.
Rules of thumb on reported numbers. A starting point, not a recommendation.
Key numbers, fiscal 2025
Market cap
Last close times the latest diluted share count, so it is approximate.
$1.8B
Oct 23 close
P/E
Last close divided by diluted earnings per share over the last four quarters.
β
On β$2.34 EPS (TTM)
Charts by
Sales and profit
Is it selling more, and how much does it keep?
Revenue and margins
In plain words: Revenue is all the money customers paid. The margins show how many cents of each dollar of sales are left over at each step: after making the product (gross), after running the business (operating) and after everything, tax included (net).
Revenue
FY24
Revenue $168M
FY25
Revenue β
Revenue
Q1 '24
Revenue β
Q2 '24
Revenue $165M
Q3 '24
Revenue $2.5M
Q4 '24
Revenue $0.0M
Q1 '25
Revenue β
Q2 '25
Revenue $0.0M
Q3 '25
Revenue β
Q4 '25
Revenue β
Q1 '26
Revenue $20.0M
Q2 '26
Revenue $0.0M
Margins, % of revenue
FY24
Gross β
Operating 34.4%
Net 31.2%
FCF 44.7%
FY25
Gross β
Operating β
Net β
FCF β
Gross
Operating
Net
FCF
Margins, % of revenue
Q1 '24
Gross β
Operating β
Net β
FCF β
Q2 '24
Gross β
Operating 84.6%
Net 84.3%
FCF 87.8%
Q3 '24
Gross β
Operating β969.2%
Net β990.1%
FCF β932.3%
Q4 '24
Gross β
Operating β
Net β
FCF β
Q1 '25
Gross β
Operating β
Net β
FCF β
Q2 '25
Gross β
Operating β
Net β
FCF β
Q3 '25
Gross β
Operating β
Net β
FCF β
Q4 '25
Gross β
Operating β
Net β
FCF β
Q1 '26
Gross β
Operating β132.8%
Net β121.0%
FCF β196.0%
Q2 '26
Gross β
Operating β
Net β
FCF β
Gross
Operating
Net
FCF
Net income and earnings per share
KIRA Β· Maze Therapeutics, Inc. lost $131M in fiscal 2025.
Loss periods are shown in red.
In plain words: Net income is the profit left after every cost and tax. Earnings per share (EPS) splits that profit across every share, so it shows what one share earned.
Net income
FY24
Net income $52.2M
FY25
Net income β$131M
Net income
Q1 '24
Net income β$32.5M
Q2 '24
Net income $139M
Q3 '24
Net income β$24.8M
Q4 '24
Net income β$29.6M
Q1 '25
Net income β$32.8M
Q2 '25
Net income β$33.7M
Q3 '25
Net income β$30.1M
Q4 '25
Net income β$34.6M
Q1 '26
Net income β$24.2M
Q2 '26
Net income β$44.7M
Diluted EPS
FY24
Diluted EPS $1.25
FY25
Diluted EPS β$3.05
Diluted EPS
Q1 '24
Diluted EPS β$13.91
Q2 '24
Diluted EPS $3.22
Q3 '24
Diluted EPS β$10.25
Q4 '24
Diluted EPS $22.19
Q1 '25
Diluted EPS β$1.15
Q2 '25
Diluted EPS β$0.77
Q3 '25
Diluted EPS β$0.66
Q4 '25
Diluted EPS β$0.47
Q1 '26
Diluted EPS β$0.45
Q2 '26
Diluted EPS β$0.76
Cash and shareholders
How much cash comes in, and where does it go?
Cash flow
KIRA Β· Free cash flow was β$113M in fiscal 2025, β of revenue.
Cash from operations minus capital spending.
In plain words: Profit on paper is not the same as cash in the bank. Free cash flow is the cash left after paying to run and maintain the business: the money it can hand back to shareholders, save or invest.
Free cash flow
FY24
Free cash flow $74.8M
FY25
Free cash flow β$113M
Free cash flow
Q1 '24
Free cash flow β$23.7M
Q2 '24
Free cash flow $145M
Q3 '24
Free cash flow β$23.3M
Q4 '24
Free cash flow β$23.1M
Q1 '25
Free cash flow β$29.8M
Q2 '25
Free cash flow β$30.4M
Q3 '25
Free cash flow β$24.7M
Q4 '25
Free cash flow β$27.8M
Q1 '26
Free cash flow β$39.2M
Q2 '26
Free cash flow β$15.2M
Cash from operations vs capital spending
FY24
Cash from operations $76.0M
Capital spending $1.1M
FY25
Cash from operations β$112M
Capital spending $0.8M
Cash from operations
Capital spending
Cash from operations vs capital spending
Q1 '24
Cash from operations β$23.4M
Capital spending $0.3M
Q2 '24
Cash from operations $145M
Capital spending $0.2M
Q3 '24
Cash from operations β$23.2M
Capital spending $0.1M
Q4 '24
Cash from operations β$22.5M
Capital spending $0.6M
Q1 '25
Cash from operations β$29.5M
Capital spending $0.3M
Q2 '25
Cash from operations β$30.1M
Capital spending $0.4M
Q3 '25
Cash from operations β$24.6M
Capital spending $0.1M
Q4 '25
Cash from operations β$27.7M
Capital spending $0.0M
Q1 '26
Cash from operations β$39.1M
Capital spending $0.1M
Q2 '26
Cash from operations β$15.1M
Capital spending $0.1M
Cash from operations
Capital spending
Dividends, buybacks and share count
In plain words: Companies hand cash back in two ways: dividends (cash paid to shareholders) and buybacks (buying back their own shares, so each remaining share owns a bigger slice).
Dividends and buybacks
FY24
Dividends β
Buybacks β
FY25
Dividends β
Buybacks β
Dividends
Buybacks
Diluted shares outstanding (annual)
FY24
Diluted shares 0.00B
FY25
Diluted shares 0.04B
Insider trades
KIRA Β· In the last 12 months, insiders sold $23.7M of shares on the open market and bought none.
Open-market purchases and sales by officers, directors and 10% owners, from Form 4 filings. βPlanβ marks trades under a pre-arranged Rule 10b5-1 plan.
In plain words: Insiders are the people who run or own a big part of the company. Buying with their own money can signal confidence; selling often has personal reasons, like taxes or diversifying.
Bought, 12 months
$0.0M
0 insiders
Sold, 12 months
$23.7M
6 insiders
Of sales under plans
90%
$21.4M
| Date | Insider | Trade | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| Oct 1, 2026 | Harold BernsteinPresident, R&D & CMO | Sold plan | 16,141 | $26.93 | $0.4M | Form 4 |
| Oct 1, 2026 | Jason Coloma VChief Executive Officer, Director | Sold plan | 34,501 | $27.02 | $0.9M | Form 4 |
| Sep 29, 2026 | Atul DandekarCsbo | Sold plan | 7,500 | $27.06 | $0.2M | Form 4 |
| Sep 4, 2026 | Harold BernsteinPresident, R&D & CMO | Sold plan | 9,705 | $26.22 | $0.3M | Form 4 |
| Sep 3, 2026 | Jason Coloma VChief Executive Officer, Director | Sold | 11,411 | $26.01 | $0.3M | Form 4 |
| Sep 3, 2026 | Phillips CourtneyGC and Corp. Secretary | Sold | 2,012 | $26.01 | $0.1M | Form 4 |
| Sep 3, 2026 | Harold BernsteinPresident, R&D & CMO | Sold | 5,189 | $26.01 | $0.1M | Form 4 |
| Sep 3, 2026 | Atul DandekarCsbo | Sold | 3,243 | $26.01 | $0.1M | Form 4 |
| Sep 2, 2026 | Phillips CourtneyGC and Corp. Secretary | Sold | 1,981 | $26.47 | $0.1M | Form 4 |
| Sep 2, 2026 | Harold BernsteinPresident, R&D & CMO | Sold | 5,106 | $26.47 | $0.1M | Form 4 |
| Sep 2, 2026 | Jason Coloma VChief Executive Officer, Director | Sold | 11,227 | $26.47 | $0.3M | Form 4 |
| Sep 2, 2026 | Atul DandekarCsbo | Sold | 3,191 | $26.47 | $0.1M | Form 4 |
| Sep 1, 2026 | Jason Coloma VChief Executive Officer, Director | Sold plan | 34,501 | $26.29 | $0.9M | Form 4 |
| Sep 1, 2026 | Harold BernsteinPresident, R&D & CMO | Sold plan | 16,141 | $26.36 | $0.4M | Form 4 |
| Aug 28, 2026 | Atul DandekarCsbo | Sold plan | 7,500 | $27.58 | $0.2M | Form 4 |
| Aug 13, 2026 | Harold BernsteinPresident, R&D & CMO | Sold plan | 16,142 | $27.61 | $0.4M | Form 4 |
| Aug 3, 2026 | Jason Coloma VChief Executive Officer, Director | Sold plan | 34,501 | $26.73 | $0.9M | Form 4 |
| Jul 29, 2026 | Atul DandekarCsbo | Sold plan | 7,500 | $27.34 | $0.2M | Form 4 |
| Jul 1, 2026 | Jason Coloma VChief Executive Officer, Director | Sold plan | 34,501 | $29.97 | $1.0M | Form 4 |
| Jul 1, 2026 | Harold BernsteinPresident, R&D & CMO | Sold plan | 14,609 | $29.91 | $0.4M | Form 4 |
| Jun 29, 2026 | Atul DandekarCsbo | Sold plan | 7,500 | $28.02 | $0.2M | Form 4 |
| Jun 23, 2026 | Jason Coloma VChief Executive Officer, Director | Sold plan | 23,865 | $26.05 | $0.6M | Form 4 |
| Jun 22, 2026 | Jason Coloma VChief Executive Officer, Director | Sold plan | 3,993 | $26.00 | $0.1M | Form 4 |
| Jun 1, 2026 | Jason Coloma VChief Executive Officer, Director | Sold plan | 6,643 | $26.20 | $0.2M | Form 4 |
| Jun 1, 2026 | Harold BernsteinPresident, R&D & CMO | Sold plan | 14,853 | $25.66 | $0.4M | Form 4 |
| May 29, 2026 | Atul DandekarCsbo | Sold plan | 7,500 | $26.34 | $0.2M | Form 4 |
| May 26, 2026 | Jason Coloma VChief Executive Officer, Director | Sold plan | 25,582 | $26.02 | $0.7M | Form 4 |
| May 22, 2026 | Jason Coloma VChief Executive Officer, Director | Sold plan | 6,982 | $26.00 | $0.2M | Form 4 |
| May 15, 2026 | Jason Coloma VChief Executive Officer, Director | Sold plan | 1,938 | $26.00 | $0.1M | Form 4 |
| May 14, 2026 | Harold BernsteinPresident, R&D & CMO | Sold plan | 15,000 | $26.22 | $0.4M | Form 4 |
| Apr 29, 2026 | Atul DandekarCsbo | Sold plan | 7,500 | $25.37 | $0.2M | Form 4 |
| Apr 1, 2026 | Harold BernsteinPresident, R&D & CMO | Sold plan | 15,000 | $29.46 | $0.4M | Form 4 |
| Apr 1, 2026 | Amy BachrodtSVP, Finance | Sold plan | 2,500 | $29.44 | $0.1M | Form 4 |
| Mar 30, 2026 | Atul DandekarCsbo | Sold plan | 7,500 | $29.34 | $0.2M | Form 4 |
| Mar 20, 2026 | Harold BernsteinPresident, R&D & CMO | Sold plan | 15,000 | $49.10 | $0.7M | Form 4 |
| Mar 10, 2026 | Harold BernsteinPresident, R&D & CMO | Sold plan | 30,000 | $50.46 | $1.5M | Form 4 |
| Mar 2, 2026 | Amy BachrodtSVP, Finance | Sold plan | 5,000 | $45.20 | $0.2M | Form 4 |
| Feb 27, 2026 | Atul DandekarCsbo | Sold plan | 7,500 | $45.43 | $0.3M | Form 4 |
| Feb 2, 2026 | Harold BernsteinPresident, R&D & CMO | Sold plan | 15,000 | $46.02 | $0.7M | Form 4 |
| Feb 2, 2026 | Amy BachrodtSVP, Finance | Sold plan | 5,000 | $46.04 | $0.2M | Form 4 |
| Jan 29, 2026 | Atul DandekarCsbo | Sold plan | 7,500 | $44.26 | $0.3M | Form 4 |
| Jan 22, 2026 | Amy BachrodtSVP, Finance | Sold plan | 5,000 | $45.52 | $0.2M | Form 4 |
| Jan 7, 2026 | Harold BernsteinPresident, R&D & CMO | Sold plan | 25,156 | $40.20 | $1.0M | Form 4 |
| Jan 7, 2026 | Catherine A. SohnDirector | Sold | 26,920 | $39.11 | $1.1M | Form 4 |
| Jan 6, 2026 | Catherine A. SohnDirector | Sold | 2,493 | $38.62 | $0.1M | Form 4 |
| Jan 5, 2026 | Harold BernsteinPresident, R&D & CMO | Sold plan | 412 | $40.00 | $0.0M | Form 4 |
| Jan 2, 2026 | Harold BernsteinPresident, R&D & CMO | Sold plan | 4,432 | $40.43 | $0.2M | Form 4 |
| Jan 2, 2026 | Amy BachrodtSVP, Finance | Sold plan | 5,000 | $39.15 | $0.2M | Form 4 |
| Dec 30, 2025 | Atul DandekarCsbo | Sold plan | 100 | $40.36 | $0.0M | Form 4 |
| Dec 30, 2025 | Amy BachrodtSVP, Finance | Sold plan | 5,000 | $40.08 | $0.2M | Form 4 |
| Dec 29, 2025 | Amy BachrodtSVP, Finance | Sold plan | 10,000 | $40.58 | $0.4M | Form 4 |
| Dec 29, 2025 | Harold BernsteinPresident, R&D & CMO | Sold plan | 45,000 | $40.57 | $1.8M | Form 4 |
| Dec 29, 2025 | Atul DandekarCsbo | Sold plan | 72,400 | $40.56 | $2.9M | Form 4 |
Financial health
Can it carry its debts, and how well does it use its money?
Balance sheet
Cash, debt and the ratios that show how comfortably Maze Therapeutics, Inc. can carry it.
In plain words: What the company owns and what it owes. More cash than debt is a cushion for bad times; a lot of debt leaves less room when business slows down.
Cash vs debt (incl. leases)
FY24
Cash $197M
Debt β
FY25
Cash $342M
Debt β
Cash
Debt
| Fiscal year end | FY24 | FY25 |
|---|---|---|
| Cash and short-term investments | $197M | $342M |
| Current ratio | 9.8x | 15.5x |
| Quick ratio | 9.8x | 15.5x |
| Total assets | $241M | $397M |
| Total liabilities | $43.6M | $42.2M |
| Shareholders' equity | β$311M | $355M |
| Net debt (β = net cash) | β | β |
Returns on capital
After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
In plain words: How much profit the business makes on the money put into it. A higher percentage means each dollar invested works harder.
Return on capital, equity and assets (annual)
FY24
Return on capital β
Return on equity β
Return on assets 21.7%
FY25
Return on capital β
Return on equity β599.0%
Return on assets β41.1%
Return on capital
Return on equity
Return on assets
Piotroski F-score
Nine pass/fail tests of profitability, funding and efficiency. 8β9 is strong, 0β2 weak.
In plain words: Nine yes/no tests of financial health, one point each. A green tick is a pass: 7 to 9 points is solid, 0 to 3 is weak.
| Test | FY24 | FY25 |
|---|---|---|
| Net income is positive | β | β |
| Cash from operations is positive | β | β |
| Return on assets rose | β | β |
| Cash from operations exceeds net income | β | β |
| Debt fell relative to assets | β | β |
| Current ratio rose | β | β |
| Share count didn't rise | β | β |
| Gross margin rose | β | β |
| Revenue rose relative to assets | β | β |
| F-score | β / 3 | β / 6 |
| Accruals ratio | β9.9% | β6.0% |
| Altman Z'' | β5.80 | 7.81 |
All figures
Every number, year by year.
2 years of figures
Amounts in USD. Hover a ratioβs name for its definition.
In plain words: Every number we have, year by year. Download it as a spreadsheet if you want to dig deeper.
| Fiscal year | FY24 | FY25 |
|---|---|---|
| Income statement | ||
| Revenue | $168M | β |
| Research and development | $83.5M | $108M |
| Operating income | $57.6M | β$143M |
| Pretax income | $53.4M | β$131M |
| Income tax | $1.2M | $0.0M |
| Net income | $52.2M | β$131M |
| Net income to common | $3.4M | β$131M |
| Diluted EPS | $1.25 | β$3.05 |
| Diluted shares | 0.00B | 0.04B |
| Cash flow | ||
| Cash from operations | $76.0M | β$112M |
| Capital expenditure | $1.1M | $0.8M |
| Free cash flow | $74.8M | β$113M |
| Depreciation and amortization | $3.3M | $2.4M |
| Stock-based compensation | $9.6M | $16.4M |
| Balance sheet | ||
| Cash and short-term investments | $197M | $342M |
| Current assets | $202M | $350M |
| Current liabilities | $20.7M | $22.6M |
| Property and equipment, net | $6.7M | $5.0M |
| Total assets | $241M | $397M |
| Total liabilities | $43.6M | $42.2M |
| Preferred stock | $0.0M | $0.0M |
| Shareholders' equity | β$311M | $355M |
| Margins | ||
| Operating margin | 34.4% | β |
| EBITDA margin | 36.3% | β |
| Net margin | 31.2% | β |
| FCF margin | 44.7% | β |
| Returns | ||
| Return on capital employed | 26.2% | β38.2% |
| Return on equity | β | β599.0% |
| Return on assets | 21.7% | β41.1% |
| Return on tangible equity | β | β36.9% |
| Growth | ||
| Net income growth | β | β351.0% |
| EPS growth | β | β344.0% |
| FCF growth | β | β250.7% |
| Share count change | β | 1,474.0% |
| Financial health | ||
| Current ratio | 9.8x | 15.5x |
| Quick ratio | 9.8x | 15.5x |
| Capital allocation | ||
| Capex / revenue | 0.7% | β |
| Stock comp / revenue | 5.8% | β |
| Quality scores | ||
| Altman Z'' | β5.8 | 7.8 |
| Accruals ratio | β9.9% | β6.0% |
Source: SEC EDGAR XBRL filings (CIK 0001842295). Data updated October 24, 2026. Quarterly fourth quarters are the full year minus the first nine months. For information only β not investment advice. Check the original filings before relying on any figure.